Table 3.
Change in serum hormones and growth factors from baseline to post-intervention. Median, range, [interquartile range], and mean ± standard deviation are shown for the 25 subjects.
| Variable or Biomarker | Baseline | Post-Intervention | Change | P-value |
|---|---|---|---|---|
| Collected at time of RPFNA (day 1–10 of menstrual cycle) | ||||
| SHBG (with E2), nM | 82 18 – 221 [38 – 124] 90 ± 56 |
68 25 – 154 [41 – 92] 73 ± 37 |
1 −140 – 43 [−54 – 18] −18 ± 51 |
0.46 |
| Estradiol, pg/ml | 88 <20* – 615 [56 – 131] 112 ± 115 |
190 <20* – 312 [120 – 224] 174 ± 76 |
80 * −481 – 247 [35 – 129] 62 ± 136 |
0.001 |
| Serum Estradiol, nM | 0.32 <0.07* – 2.28 [0.21 – 0.49] 0.41 ± 0.43 |
0.70 <0.07* – 1.15 [0.45 – 0.83] 0.64 ± 0.28 |
0.29 * −1.79 – 0.92 [0.14 – 0.48] 0.23 ± 0.51 |
|
| Bioavailable (Free) Estradiol, pM | 4.5 0.7 – 31.1 [1.4 – 6.4] 5.3 ± 6.2 |
8.0 1.2 – 15.7 [5.3 – 10.8] 7.8 ± 3.4 |
3.5 * −25.5 – 10.1 [1.0 – 7.0] 2.6 ± 7.0 |
0.002 |
| Collected at day 20–24 of menstrual cycle | ||||
| IGF-1, ng/ml | 129 72 – 223 [107 – 167] 139 ± 42 |
146 71 – 220 [103 – 173] 141 ± 41 |
3 −41 – 66 [−15 – 18] 2 ± 27 |
0.74 |
| IGF-1, nM | 16.8 9.4 – 29.0 [13.9 – 21.7] 18.1 ± 5.4 |
19.0 9.3 – 28.6 [13.4 – 22.6] 18.3 ± 5.3 |
0.4 −5.4 – 8.6 [−1.9 – 2.3] 0.3 ± 3.5 |
|
| IGFBP-3, ng/ml | 2350 1505–3683 [2061 – 3025] 2504 ± 609 |
2667 1497–3556 [2249 – 3006] 2618 ± 539 |
111 −307–1239 [−62 – 246] 114 ± 267 |
0.051 |
| IGFBP-3, nM | 82.3 52.7 – 128.9 [72.1 – 105.9] 87.6 ± 21.3 |
93.4 52 – 124 [78.7 – 105.2] 92 ± 19 |
3.9 −10.7 –32.6 [−2.2 – 8.6] 4.0 ± 9.3 |
|
| IGF-1:IGFBP-3 Molar Ratio | 0.21 0.10 – 0.37 [0.16 – 0.25] 0.21 ± 0.06 |
0.19 0.10 – 0.42 [0.16 – 0.24] 0.21 ± 0.07 |
−0.01 −0.12 – 0.11 [−0.03 – 0.02] −0.01 ± 0.05 |
0.41 |
| Progesterone, ng/ml | 3.5 0.4 – 26.2 [0.9 – 3.5] 4.4 ± 5.5 |
2.8 0.5 – 36.3 [0.7 –9.7] 7.1 ± 10.0 |
0.0 −10.7 – 30.1 [−2.6 – 1.9] 2.7 ± 9.7 |
0.78 |
| Progesterone, nM | 11.0 1.1 – 83.3 [2.7 – 18.8] 14.0 ± 17.3 |
8.9 1.5 – 115.3 [2.1 – 30.7] 22.6 ± 31.7 |
−0.1 −34.1 – 95.8 [−8.3 – 6.1] 8.6 ± 30.7 |
|
| SHBG, nM | 87 22 – 276 [59 – 193] 117 ± 80 |
85 34 – 179 [48 – 135] 93 ± 46 |
6 −227 – 60 [−45 – 18] −24 ± 73 |
0.53 |
| Testosterone, ng/ml | 0.40 <0.08* – 2.59 [0.18 – 0.83] 0.63 ± 0.64 |
0.58 0.19 – 3.52 [0.29 – 0.83] 0.85 ± 0.91 |
0.16 −0.21 – 2.33 [0.02 – 0.24] 0.22 ± 0.48 |
0.002 |
| Testosterone, nM | 1.37 <0.28* – 9.00 [0.63 – 2.87] 2.18 ± 2.21 |
2.0 0.64 – 12.21 [1.00 – 2.86] 2.93 ± 3.15 |
0.53 −0.74 – 8.09 [0.06 – 0.80] 0.75 ± 1.66 |
|
| Bioavailable (Free) Testosterone, pM | 13.4 1.1 – 120.2 [4.6 – 35.1] 25.1 ± 30.7 |
17.3 3.8 – 194.4 [9.5 – 38.3] 32.4 ± 41.6 |
4.1 −26.9 – 118.2 [−2.1 – 8.5] 7.3 ± 26.8 |
0.13 |
*
One woman had estradiol levels below limit of detection at both times and was imputed to have no change. Another women had testosterone levels below limit of detection only at baseline and was considered to have exhibited an increase.